Cadence Pharmaceuticals Inc. (CADX)
Q2 2010 Earnings Call
August 05, 2010
Ted Schroeder - President and CEO
Jim Breitmeyer - EVP and Chief Medical Officer
Bill LaRue - EVP and CFO
Charles Duncan - JMP Securities
Eric Schmidt - Cowen and Company
Adam Cutler - Canaccord
Greg Fraser - Banc of America-Merrill Lynch
John Newman - Oppenheimer
Welcome to the Cadence Pharmaceuticals Second Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO, Jim Breitmeyer, Executive Vice President and Chief Medical Officer, and Bill LaRue, Senior Vice President and Chief Financial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. (Operator Instruction)
Our first is speaker is Bill LaRue. Go ahead, sir.
Before we get started today, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding: the timeframe in which the FDA is expected to complete its review of our NDA for OFIRMEV, and our belief that our NDA will be sufficient for the FDA to approve this product candidate; our readiness to launch OFIRMEV, and the potential strength of any such launch; the sufficiency of the our capital resources to fund our operations through the approval of initial launch period of OFIRMEV; our ability to complete future drawdowns under our loan facility; the potential for us acquire Incline Therapeutics and the anticipated strategic benefit of any such acquisition, and all of our financial estimates and projections.